Cardiac resynchronization therapy improves quality of life, exercise capacity, and cardiac function, and reduces heart failure hospitalizations and overall mortality in patients with heart failure.
The definition of CRT response is highly variable and dependent on the criteria used, highlighting the need to align clinical trial endpoints with real-world patient expectations of symptomatic improvement and reverse remodeling.
Cardiac resynchronization therapy (CRT) improves quality of life, exercise capacity, and cardiac function in a significant number of patients with heart failure (HF) and left bundle branch block. CRT also reduces HF hospitalizations and overall mortality. A substantial number of patients however do not have a favorable clinical response. Evaluation of CRT non-response has been challenging as the primary mechanism for CRT improvement remains elusive. In addition, reported CRT response rates have varied significantly and are highly dependent on the criteria used to define the response. Futhermore, a disconnection exists between applying the outcome data from large clinical trials to the ''real world'' expectations of daily clinical practice. The ultimate goals of CRT should both met the patients' expectations for symptomatic improvement and also improve cardiac function and/or outcomes.
Gery Tomassoni (Mon,) conducted a review in Heart failure. Cardiac resynchronization therapy (CRT) was evaluated. Cardiac resynchronization therapy improves quality of life, exercise capacity, and cardiac function, and reduces heart failure hospitalizations and overall mortality in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: